CanSino Biologics (HKG:6185) recorded a net profit attributable to shareholders of 3.0 million yuan for the third quarter of 2024 while the Earnings per share stood at 0.01 yuan for the reporting period, a Tuesday filing with the Hong Kong Exchange said.
The vaccine company's operating revenue for the three months ended Sept. 30 was 263.6 million yuan, 76.09% higher than a year ago.
The company's shares were down nearly 2% on Tuesday's close.
Price (HKD): $26.20, Change: $-0.45, Percent Change: -1.69%